BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:HE@Cam: Peter Morten - New therapies\, new methods: the use of nov
 el survival analysis methods for I-O therapies - Peter Morten - Costello M
 edical
DTSTART:20181105T150000Z
DTEND:20181105T160000Z
UID:TALK112777@talks.cam.ac.uk
CONTACT:Patricia Peinado - Assistant Professor
DESCRIPTION:Health Economics at Cambridge (HE@Cam) are pleased to present 
 Peter Morten\, Costello Medical\, for a seminar on Immuno-oncology (I-O) t
 herapies. This novel approach to fighting certain types of cancer has been
  clinically effective\, but also poses a new set of challenges for those t
 rying to assess its effectiveness. In his talk\, Peter will discuss early 
 approaches to survival modelling with I-O therapies in the UK\, and the me
 thodological demands of future health technology assessment.\n\nInformatio
 n can also be found "here":http://www.publichealth.cam.ac.uk/seminar-05-no
 v-2018-peter-morten/\n\n*Time:* 15:00-16:00 Monday 5th November 2018\n*Ven
 ue:* Large seminar room\, Institute of Public Health\, Cambridge\n\n*All W
 elcome. Part of HE@Cam seminar 2018/19 series.*\n\n*About the seminar:*\nI
 mmuno-oncology (I-O) therapies have emerged in the last few years as promi
 sing cancer treatments. These therapies present a novel mechanism of actio
 n – essentially removing the “brakes” placed on the body’s immune 
 system by tumours – and have proven clinically effective across an ever-
 growing range of tumour types.\n\nThe survival profiles for patient popula
 tions treated with these I-O therapies have shown emerging evidence of not
 able features\, including a plateau in the overall survival curve and evid
 ence of a delayed clinical effect. Based on this\, standard parametric dis
 tributions\, which are recommended by the NICE Decision Support Unit\, may
  not be adequate to model these complex survival functions over the long t
 erm. As such\, recent health technology assessments (HTAs) have seen the a
 pplication by manufacturers of alternative approaches to modelling surviva
 l with I-O therapies\, including mixture cure models and response-based mo
 dels.\n\nThis talk will present a review of the use and acceptance (or lac
 k thereof) of alternative survival modelling approaches for I-O therapies 
 in UK HTA. The challenges and barriers to acceptance of these methods by d
 ecision-makers will be discussed\, alongside perspectives on potential dev
 elopments in this area in the near future.\n\n*Peter Morten:*\nPeter is a 
 Consultant in the HTA and Health Economics division at Costello Medical\, 
 a medical communications and health economics consultancy founded in Cambr
 idge and now based in Cambridge\, London and Singapore. Peter’s role inv
 olves leading the development of pharmaceutical companies’ written submi
 ssions of evidence to HTA bodies like NICE in England and Wales and the SM
 C in Scotland\, as well as the development of the health economic models t
 hat provide the evidence around cost-effectiveness for these submissions. 
 Peter has worked in the field of HTA for I-O therapies for the last two ye
 ars\; hence the inspiration for his interest in this area.\n
LOCATION:Large Seminar Room\, Institute of Public Health\, Cambridge
END:VEVENT
END:VCALENDAR